PMID- 30986693
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 113
DP  - 2019 Jun
TI  - Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and 
      schizophrenia.
PG  - 190-198
LID - S0022-3956(18)31219-6 [pii]
LID - 10.1016/j.jpsychires.2019.03.024 [doi]
AB  - The role of brain-derived neurotrophic factor (BDNF) and its related molecules 
      has been extensively studied in the context of psychiatric disorders. In the 
      present study, we focused on the newly identified BDNF pro-peptide, which is 
      generated together with mature BDNF by proteolytic processing of their precursor, 
      proBDNF. Here, we report, for the first time, that BDNF pro-peptide is present in 
      human cerebrospinal fluid (CSF) and quantifiable by western blotting. We measured 
      CSF BDNF pro-peptide levels in 27 patients with schizophrenia, 18 patients with 
      major depressive disorder (MDD), and 27 healthy controls matched for age, sex, 
      and ethnicity (Japanese). The ratio of the BDNF pro-peptide level to the total 
      protein level in MDD patients was significantly lower than that in controls 
      (Kruskal-Wallis with Dunn's multiple comparisons test; p = 0.046). When men and 
      women were examined separately, males with MDD had a significantly lower BDNF 
      pro-peptide/protein ratio than male controls (p = 0.047); this difference was not 
      found in female subjects. The ratio tended to be lower in male schizophrenia 
      patients (p = 0.10). Although we tried to measure the levels of mature BDNF in 
      CSF, they were below the limit of detection of the ELISA and multiple analyte 
      profiling technology. Taken together, the results suggest that reduced CSF BDNF 
      pro-peptide levels are associated with MDD, particularly in males. Further 
      studies involving a larger sample size are warranted.
CI  - Copyright (c) 2019. Published by Elsevier Ltd.
FAU - Mizui, Toshiyuki
AU  - Mizui T
AD  - Biomedical Research Institute (BMD), National Institute of Advanced Industrial 
      Science and Technology (AIST), Osaka 563-8577, Japan.
FAU - Hattori, Kotaro
AU  - Hattori K
AD  - Department of Mental Disorder Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, Tokyo, 187-8502, Japan; Medical 
      Genome Center, National Center of Neurology and Psychiatry, Tokyo, 187-8502, 
      Japan.
FAU - Ishiwata, Sayuri
AU  - Ishiwata S
AD  - Department of Mental Disorder Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, Tokyo, 187-8502, Japan.
FAU - Hidese, Shinsuke
AU  - Hidese S
AD  - Department of Mental Disorder Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, Tokyo, 187-8502, Japan.
FAU - Yoshida, Sumiko
AU  - Yoshida S
AD  - Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, 
      187-8502, Japan; National Center of Neurology and Psychiatry Hospital, Tokyo, 
      187-8502, Japan.
FAU - Kunugi, Hiroshi
AU  - Kunugi H
AD  - Department of Mental Disorder Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, Tokyo, 187-8502, Japan. Electronic 
      address: hkunugi@ncnp.go.jp.
FAU - Kojima, Masami
AU  - Kojima M
AD  - Biomedical Research Institute (BMD), National Institute of Advanced Industrial 
      Science and Technology (AIST), Osaka 563-8577, Japan; Graduate School of Frontier 
      Bioscience, Osaka University, Suita 565-0871, Japan. Electronic address: 
      m-kojima@aist.go.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190326
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/*cerebrospinal fluid
MH  - Depressive Disorder, Major/*cerebrospinal fluid
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Schizophrenia/*cerebrospinal fluid
OTO - NOTNLM
OT  - BDNF
OT  - BDNF pro-peptide
OT  - Human cerebrospinal fluid
OT  - Major depressive disorder
OT  - Schizophrenia
EDAT- 2019/04/16 06:00
MHDA- 2020/07/02 06:00
CRDT- 2019/04/16 06:00
PHST- 2018/10/10 00:00 [received]
PHST- 2019/03/21 00:00 [revised]
PHST- 2019/03/22 00:00 [accepted]
PHST- 2019/04/16 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2019/04/16 06:00 [entrez]
AID - S0022-3956(18)31219-6 [pii]
AID - 10.1016/j.jpsychires.2019.03.024 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2019 Jun;113:190-198. doi: 10.1016/j.jpsychires.2019.03.024. 
      Epub 2019 Mar 26.